COMP <GO>
LLY vs NVO // GROSS PROFIT MARGIN
Eli Lilly and Company (NYSE) VS. Novo Nordisk A/S (NYSE) • 15-METRIC TALLY: LLY 10
— NVO 3
■ METRIC PARITY
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
gross-margins
83.64%
LAST: $40.00 (+2.20%) • MKT CAP: $173.31B
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LLY VS. NVO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LLY | NVO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 83.64% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.36% | 9.90% | +22.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 36.4x | 21.0x | +15.42 | NVO | /valuation <GO> |
| Free Cash Flow Yield | 2.30% | 2.21% | +0.09 | LLY | /fcf-yield <GO> |
| Operating Margin | 40.21% | 13.90% | +26.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | 31.90% | 10.90% | +21.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 45.51% | 2.20% | +43.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.49% | 0.00% | +0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.29 | 3.74 | +5.55 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.77% | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.6 | 47.9 | +18.70 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.51 | 0.87 | -0.36 | NVO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.6x | 30.5x | +0.12 | NVO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29T | $173.31B | $1.12T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LLY REV | NVO REV | LLY GROSS % | NVO GROSS % | LLY FCF | NVO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $65.18B | — | 83.0% | — | $16.81B | — |
| FY 2024 | $45.04B | — | 81.3% | — | $8.82B | — |
| FY 2023 | $34.12B | — | 79.3% | — | $4.24B | — |
| FY 2022 | $28.54B | — | 76.8% | — | $7.59B | — |
| FY 2021 | $28.32B | — | 74.2% | — | $7.37B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LLY // BETA 0.51
NVO // BETA 0.87